Current medical treatments are aimed at preventing the progression of the AMD by treating the CNV membranes with intravitreal injections of anti-vascular endothelial growth factor (anti-VEGF),[2] triamcinolone,[3] photodynamic therapy,[4] or laser photocoagulation.[5] However, if the retinal pigment epithelium (RPE) underlying the fovea is damaged severely, the medical treatments have limited effects on the best-corrected visual acuity (BCVA). The gene discussed is VEGFA; the disease is age-related macular degeneration.